Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details)

v3.19.1
Collaboration and License Agreements and Supply Agreements - Summary of Recognized Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 8,629 $ 5,793
Collaboration and License Agreements and Supply Agreements    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 8,629 5,793
Collaboration and License Agreements and Supply Agreements | Celgene    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 1,575 4,084
Collaboration and License Agreements and Supply Agreements | Merck    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 4,635 0
Collaboration and License Agreements and Supply Agreements | SutroVax    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue 281 0
Collaboration and License Agreements and Supply Agreements | Merck KGaA, Darmstadt, Germany “EMD Serono”)    
Revenue Recognition Multiple Deliverable Arrangements [Line Items]    
Total revenue $ 2,138 $ 1,709